Furosemide
As of the edition of 20 October 2026, Furosemide is a small molecule: marketed, first approved in 1964 (ES); acts on SLC12A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Lasix
- First approved
- 1 July 1964 (ES)
- Approvals on record
- 53 in 7 regions
- Holder of the most recent approval
- Scpharmaceuticals Inc A Wholly Owned Sub Of Mannkind; 24 holders in all
- Registered trials
- 181, 19 stopped early
- Disease areas
- Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Nutrition and metabolism; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Furosemide.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC12A1 | Solute carrier family 12 member 1 | Q13621 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 40 | 20 | 10 | 5 |
| Phase 1 | 42 | 38 | 2 | 1 |
| Phase 2 | 30 | 22 | 3 | 3 |
| Phase 3 | 32 | 13 | 10 | 2 |
| Phase 4 | 37 | 20 | 7 | 8 |
| All trials | 181 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Applicant, Later holder and Lead sponsor of trials | 1964 to now |
| Warner Chilcott | Later holder | 1982 to now |
| Lundbeck | Later holder | 1982 to now |
| Abbott | Later holder | 1982 to now |
| Pfizer | Acquired holder, Later holder and Lead sponsor of trials | 1982 to now |
| Astellas | Later holder and Lead sponsor of trials | 1982 to now |
| Superpharm | Later holder | 1983 to now |
| Kalapharm | Later holder | 1983 to now |
| Hikma Pharmaceuticals | Acquired holder and Later holder | 1983 to now |
| Teva | Later holder | 1983 to now |
| Vitarine Pharmaceuticals | Later holder | 1984 to now |
| Actavis | Acquired holder | 2003 to now |
| Amphastar Pharmaceuticals | Acquired holder | 2003 to now |
| International Medication System | Acquired holder | 2003 to now |
| Abraxis Pharmaceutical | Acquired holder | 2006 to now |
| Fresenius Kabi | Acquired holder | 2013 to now |
| Mannkind | Later holder and Lead sponsor of trials | 2014 to now |
| SUN Pharmaceutical Industries | Acquired holder | 2018 to now |
| Baxter Healthcare | Applicant | 2019 to now |
| SQ Innovation | Later holder and Lead sponsor of trials | 2020 to now |
| American Regent | Acquired holder | 2020 to now |
| Validus Pharmaceuticals | Acquired holder | 2021 to now |
| Epic Pharma | Acquired holder | 2022 to now |
| Chartwell Rx Sciences | Acquired holder | 2023 to now |
| Esjay Pharma | Acquired holder | 2024 to now |
| Pharmobedient Consulting | Acquired holder | 2025 to now |
| Proveca Pharma | Applicant | 2026 to now |
| Scpharmaceuticals Inc A Wholly Owned Sub Of Mannkind | Acquired holder | 2026 to now |
| Cord | Later holder | |
| Viatris | Later holder |